PHILADELPHIA, Feb. 5, 2019 /PRNewswire-PRWeb/ -- Proscia, a pioneer in the development and advancement of digital pathology,
The Commercial Research Edition extends Proscia's Concentriq platform with new features and enterprise scalability that pharmaceutical, biotechnology, and commercial research organizations (CROs) require to better realize the true promise of digital pathology. The capabilities of this single centralized platform empower life science teams to streamline workflows, integrate with third party systems, cut costs, and extract critical insights from massive quantities of images.
"Having a comprehensive digital pathology solution specifically designed for the needs of scientists and pathologists allows them to focus on research and discovery instead of wasting valuable time on tedious image management and data gathering," explained Nathan Buchbinder, Chief Product Officer of Proscia. "By perfecting research with intelligent software, we are changing the way the world practices pathology and helping life sciences organizations bring new discoveries to market faster and at a lower cost."
The new Concentriq Commercial Research Edition offers a comprehensive image management solution with features essential to maximizing digital pathology investment and efficiency within research laboratories. Some of these include:
"As a global provider of neurohistological services to a broad spectrum of organizations within the research industry, we consistently strive to improve our technologies and services to deliver the highest quality histology, imaging, and analysis to our clients at an expedited rate," explained Tate York, Director of Digital Microscopy and Image Analysis at NeuroScience Associates. "Having a comprehensive digital histology solution was the last piece of the puzzle we needed to tie our neurohistology services with our digital workflow. With Concentriq, we can now rapidly provide our clients with both the images and the associated data in a user-friendly way, ultimately speeding up the research process."
Life sciences organizations have been on the forefront of digital pathology adoption in an effort to better assimilate data from multiple sources and leverage the hidden data trapped in physical glass slides; however, the transition to digital has introduced a new set of complexities. These organizations are now facing new challenges, including managing a massive number of images and associated data, ensuring accessibility, and integrating with existing systems and workflows. Proscia's Concentriq platform takes digital pathology to the next level by eliminating the data bottlenecks that prevent teams from realizing the full promise of digitization.
Proscia's Concentriq Digital Pathology Platform is an enterprise-class suite of digital pathology solutions for whole-slide image, data, and workflow management. There are now three editions of the platform: Concentriq Clinical Enterprise Edition*, Concentriq Academic Research & Education Edition, and Concentriq Commercial Research Edition. Concentriq's robust and scalable architecture delivers powerful digital pathology experiences that enable laboratories to increase efficiency and maximize productivity.
About Proscia Proscia was founded in 2014 by a team out of Johns Hopkins and the University of Pittsburgh to improve clinical outcomes and accelerate the discovery of breakthrough advancements in the fight against cancer. Using modern computing technologies that unlock hidden data not visible to the human eye and turning that data into valuable insights in the fight against cancer, the company is dedicated to improving the efficiency, speed, and quality of pathology diagnostics and research. http://www.proscia.com
*Concentriq is not intended for use in primary diagnosis.
SOURCE Proscia Inc.
Subscribe to our Free Newsletters!